Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $10.6 million.

  • Gyre Therapeutics' Accumulated Expenses rose 23.51% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 23.51%. This contributed to the annual value of $10.6 million for FY2024, which is 11.06% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Accumulated Expenses of $10.6 million as of FY2024, which was down 11.06% from $11.9 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Accumulated Expenses high stood at $11.9 million for FY2023, and its period low was $1.5 million during FY2021.
  • In the last 3 years, Gyre Therapeutics' Accumulated Expenses had a median value of $10.6 million in 2024 and averaged $10.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 40.75% in 2021, then soared by 531.49% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Accumulated Expenses (Yearly) stood at $2.5 million in 2020, then slumped by 40.75% to $1.5 million in 2021, then skyrocketed by 531.49% to $9.3 million in 2022, then climbed by 28.83% to $11.9 million in 2023, then decreased by 11.06% to $10.6 million in 2024.